These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 23825028)

  • 1. Meta-analysis of transcriptome reveals let-7b as an unfavorable prognostic biomarker and predicts molecular and clinical subclasses in high-grade serous ovarian carcinoma.
    Tang Z; Ow GS; Thiery JP; Ivshina AV; Kuznetsov VA
    Int J Cancer; 2014 Jan; 134(2):306-18. PubMed ID: 23825028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinicopathologic study and immunohistochemistry comparison of Pax2, p53 and Ki-67 in low- and high-grade ovarian serous carcinomas].
    Shen XX; Yu L; Bi R; Yang WT
    Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):511-6. PubMed ID: 22169637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA expression profiles in serous ovarian carcinoma.
    Nam EJ; Yoon H; Kim SW; Kim H; Kim YT; Kim JH; Kim JW; Kim S
    Clin Cancer Res; 2008 May; 14(9):2690-5. PubMed ID: 18451233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of microRNA expression in serous ovarian carcinoma.
    Li Y; Yao L; Liu F; Hong J; Chen L; Zhang B; Zhang W
    Int J Mol Med; 2014 Aug; 34(2):491-8. PubMed ID: 24939816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct microRNA expression profile in prostate cancer patients with early clinical failure and the impact of let-7 as prognostic marker in high-risk prostate cancer.
    Schubert M; Spahn M; Kneitz S; Scholz CJ; Joniau S; Stroebel P; Riedmiller H; Kneitz B
    PLoS One; 2013; 8(6):e65064. PubMed ID: 23798998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer.
    Ouellet V; Guyot MC; Le Page C; Filali-Mouhim A; Lussier C; Tonin PN; Provencher DM; Mes-Masson AM
    Int J Cancer; 2006 Aug; 119(3):599-607. PubMed ID: 16572426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of two poorly prognosed ovarian carcinoma subtypes associated with CHEK2 germ-line mutation and non-CHEK2 somatic mutation gene signatures.
    Ow GS; Ivshina AV; Fuentes G; Kuznetsov VA
    Cell Cycle; 2014; 13(14):2262-80. PubMed ID: 24879340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic and prognostic significance of miRNA signatures in tissues and plasma of endometrioid endometrial carcinoma patients.
    Torres A; Torres K; Pesci A; Ceccaroni M; Paszkowski T; Cassandrini P; Zamboni G; Maciejewski R
    Int J Cancer; 2013 Apr; 132(7):1633-45. PubMed ID: 22987275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.
    Bonome T; Lee JY; Park DC; Radonovich M; Pise-Masison C; Brady J; Gardner GJ; Hao K; Wong WH; Barrett JC; Lu KH; Sood AK; Gershenson DM; Mok SC; Birrer MJ
    Cancer Res; 2005 Nov; 65(22):10602-12. PubMed ID: 16288054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel defined programmed cell death related gene signature for predicting the prognosis of serous ovarian cancer.
    Zhan F; Guo Y; He L
    J Ovarian Res; 2024 Apr; 17(1):92. PubMed ID: 38685095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression profile of tight junction protein claudin 3 and claudin 4 in ovarian serous adenocarcinoma with prognostic correlation.
    Choi YL; Kim J; Kwon MJ; Choi JS; Kim TJ; Bae DS; Koh SS; In YH; Park YW; Kim SH; Ahn G; Shin YK
    Histol Histopathol; 2007 Nov; 22(11):1185-95. PubMed ID: 17647191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Herpes virus microRNA expression and significance in serous ovarian cancer.
    Pandya D; Mariani M; McHugh M; Andreoli M; Sieber S; He S; Dowell-Martino C; Fiedler P; Scambia G; Ferlini C
    PLoS One; 2014; 9(12):e114750. PubMed ID: 25485872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-1236-3p represses the cell migration and invasion abilities by targeting ZEB1 in high-grade serous ovarian carcinoma.
    Wang Y; Yan S; Liu X; Zhang W; Li Y; Dong R; Zhang Q; Yang Q; Yuan C; Shen K; Kong B
    Oncol Rep; 2014 Apr; 31(4):1905-10. PubMed ID: 24573236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
    Karlan BY; Dering J; Walsh C; Orsulic S; Lester J; Anderson LA; Ginther CL; Fejzo M; Slamon D
    Gynecol Oncol; 2014 Feb; 132(2):334-42. PubMed ID: 24368280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioinformatic profiling identifies a platinum-resistant-related risk signature for ovarian cancer.
    Wu C; He L; Wei Q; Li Q; Jiang L; Zhao L; Wang C; Li J; Wei M
    Cancer Med; 2020 Feb; 9(3):1242-1253. PubMed ID: 31856408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Screening and identification of potential miRNA involved in ovarian cancer invasion and metastasis].
    Liang SH; Li J; Al-beit M; Zhang J; Ma D; Lu X
    Zhonghua Zhong Liu Za Zhi; 2010 Sep; 32(9):650-4. PubMed ID: 21122376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The molecular prognostic score, a classifier for risk stratification of high-grade serous ovarian cancer.
    Sarkar S; Saha SA; Swarnakar A; Chakrabarty A; Dey A; Sarkar P; Banerjee S; Mitra P
    J Ovarian Res; 2024 Aug; 17(1):159. PubMed ID: 39095849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical significance of two-tier grading system of ovarian serous carcinoma].
    Zhang J; Guo XQ; Liu JS
    Zhonghua Fu Chan Ke Za Zhi; 2011 Oct; 46(10):739-41. PubMed ID: 22321346
    [No Abstract]   [Full Text] [Related]  

  • 19. Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma.
    Cohen S; Mosig R; Moshier E; Pereira E; Rahaman J; Prasad-Hayes M; Halpert R; Billaud JN; Dottino P; Martignetti JA
    Gynecol Oncol; 2014 Sep; 134(3):591-8. PubMed ID: 24995581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data.
    Vang R; Shih IeM; Salani R; Sugar E; Ayhan A; Kurman RJ
    Am J Surg Pathol; 2008 Nov; 32(11):1667-74. PubMed ID: 18769340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.